Endurance Tech remains a Buy recommendation by Citi, yet the target price is revised down to Rs 2,900 due to demand concerns. The financial services firm Fortis Healthcare expects an EBITDA margin of 22-25% by FY26. Jefferies predicts a 74% growth potential for Aavas Financiers, setting a target price at Rs 1,875. However, Morgan Stanley expresses caution and prefers Aptus and Home First Finance over Aavas Financiers.

Morgan Stanley maintains a neutral stance towards Aavas Financiers, suggesting an anticipated price of INR 1,600. Investors may consider this as a potential indicator for their investment strategy.

Jefferies remains optimistic about Aavas Financiers, maintaining a 'Buy' rating with a price target of Rs 1,875. The asset under management (AUM) has increased by 15% year-over-year to reach Rs 235 billion. Notable growth was also seen in disbursements, which rose by 16% YoY, and GS-3 improved to 1.07%. A total of 31 branches were added during the fourth quarter, while the price-to-book ratio stands at 1.5x for FY27E.

AAVAS Financiers' assets under management (AUM) increased by 15% year-on-year, reaching INR 235 billion, with a notable 16% growth in Q4 disbursements. The company's delinquency rate and gross non-performing loans also improved significantly, resulting in a credit rating upgrade to AAA.